{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:21:47Z","timestamp":1782487307856,"version":"3.54.5"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.semarthrit.2012.03.010","type":"journal-article","created":{"date-parts":[[2012,4,25]],"date-time":"2012-04-25T22:01:12Z","timestamp":1335391272000},"page":"155-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Treatment of Chronic Gouty Arthritis: It Is Not Just About Urate-Lowering Therapy"],"prefix":"10.1016","volume":"42","author":[{"given":"Naomi","family":"Schlesinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.semarthrit.2012.03.010_bib1","first-page":"352","article-title":"Gout: A clinical syndrome illustrated and discussed","volume":"68","author":"Bhansing","year":"2010","journal-title":"Neth J Med"},{"issue":"10","key":"10.1016\/j.semarthrit.2012.03.010_bib2","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: The national health and nutrition examination survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"21","key":"10.1016\/j.semarthrit.2012.03.010_bib3","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2165\/00003495-200464210-00003","article-title":"Management of acute and chronic gouty arthritis: Present state-of-the-art","volume":"64","author":"Schlesinger","year":"2004","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.010_bib4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3810\/pgm.2010.03.2133","article-title":"Diagnosing and treating gout: A review to aid primary care physicians","volume":"122","author":"Schlesinger","year":"2010","journal-title":"Postgrad Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.03.010_bib5","first-page":"466","article-title":"Compliance in gout patients","volume":"35","author":"Silva","year":"2010","journal-title":"Acta Reumatol Port"},{"issue":"11","key":"10.1016\/j.semarthrit.2012.03.010_bib6","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1136\/ard.2010.128454","article-title":"The pathogenesis of bone erosions in gouty arthritis","volume":"69","author":"Schlesinger","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.010_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.03.010_bib8","first-page":"908","article-title":"A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis","volume":"22","author":"Ferraz","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.03.010_bib9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMcp1001124","article-title":"Clinical practice","volume":"364","author":"Neogi","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.010_bib10","first-page":"577","article-title":"Treatment of chronic gout","volume":"28","author":"Li-Yu","year":"2001","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.010_bib11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2012.03.010_bib12","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/art.1780341203","article-title":"Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout","volume":"34","author":"McCarthy","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.03.010_bib13","first-page":"4103","article-title":"A phase 3 study comparing the safety and efficacy of oral febuxostat and allopurinol in subjects with hyperuricemia and gout","volume":"50","author":"Becker","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1016\/j.semarthrit.2012.03.010_bib14","first-page":"S335","article-title":"A phase 2, long term, open-label safety and efficacy study of febuxostat, a novel non-purine selective inhibitor of xanthine oxidase [Abstract number 800]","volume":"50","author":"Schumacher","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2012.03.010_bib15","first-page":"1383","article-title":"Withdrawal of longterm antihyperuricemic therapy in tophaceous gout","volume":"20","author":"van Lieshout-Zuidema","year":"1993","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.010_bib16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/BF02201004","article-title":"Withdrawal of longterm antihyperuricemic therapy in tophaceous gout","volume":"6","author":"Gast","year":"1987","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.010_bib17","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/ard.33.4.304","article-title":"Withdrawal of allopurinol in patients with gout","volume":"33","author":"Loebl","year":"1974","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.semarthrit.2012.03.010_bib18","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.010_bib19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","article-title":"Serum urate levels and gout flares: Analysis from managed care data","volume":"12","author":"Sarawate","year":"2006","journal-title":"J Clin Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2012.03.010_bib20","doi-asserted-by":"crossref","first-page":"ii9","DOI":"10.1093\/rheumatology\/kep087","article-title":"Treating to target: A strategy to cure gout","volume":"48","author":"Perez-Ruiz","year":"2009","journal-title":"Rheumatol Oxf Engl"},{"issue":"14","key":"10.1016\/j.semarthrit.2012.03.010_bib21","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","article-title":"Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: Analysis of data from three phase III trials","volume":"32","author":"Wortmann","year":"2010","journal-title":"Clin Ther"},{"issue":"8","key":"10.1016\/j.semarthrit.2012.03.010_bib22","first-page":"1575","article-title":"Compliance with allopurinol therapy among managed care enrollees with gout: A retrospective analysis of administrative claims","volume":"31","author":"Riedel","year":"2004","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2012.03.010_bib23","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"22","key":"10.1016\/j.semarthrit.2012.03.010_bib24","first-page":"1120","article-title":"The treatment of gout and disorders of uric acid metabolism with allopurinol","volume":"95","author":"Ogryzlo","year":"1966","journal-title":"CMAJ"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.010_bib25","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/ard.16.4.425","article-title":"Evaluation of uricosuric agents in chronic gout","volume":"16","author":"Ogryzlo","year":"1957","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.010_bib26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.26.2.136","article-title":"Allopurinol in the treatment of uraemic patients with gout","volume":"26","author":"Wilson","year":"1967","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"10.1016\/j.semarthrit.2012.03.010_bib27","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2012.03.010_bib28","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.010_bib29","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.010_bib30","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous pegylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2012.03.010_bib31","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.010_bib32","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/15257770802136032","article-title":"Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy","volume":"27","author":"Becker","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"7081","key":"10.1016\/j.semarthrit.2012.03.010_bib33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.semarthrit.2012.03.010_bib34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4615-5381-6_3","article-title":"Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment","volume":"431","author":"Yamanaka","year":"1998","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.03.010_bib35","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1185\/03007995.2011.563284","article-title":"A new perspective on the pharmacoeconomics of colchicine","volume":"27","author":"Wertheimer","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.semarthrit.2012.03.010_bib36","series-title":"COLCRYS (colchicine, USP) Tablets [prescribing information]","year":"2011"},{"key":"10.1016\/j.semarthrit.2012.03.010_bib37","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.semarthrit.2012.03.010_bib38","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2012.03.010_bib39","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1056\/NEJMp1003126","article-title":"Incentives for drug development\u2014The curious case of colchicine","volume":"362","author":"Kesselheim","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2012.03.010_bib40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-55-2-179","article-title":"Efficacy of colchicine prophylaxis in gout","volume":"55","author":"Yu","year":"1961","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2012.03.010_bib41","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/art.1780080502","article-title":"Treatment of primary gout: The present status","volume":"8","author":"Gutman","year":"1965","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.03.010_bib42","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.1780170517","article-title":"Prophylactic colchicine therapy of intercritical gout","volume":"17","author":"Paulus","year":"1974","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.semarthrit.2012.03.010_bib43","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2165\/11206330-000000000-00000","article-title":"Oral colchicine (Colcrys\u00ae) in the treatment and prophylaxis of gout: Profile report","volume":"27","author":"Yang","year":"2010","journal-title":"Drugs Aging"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.010_bib44","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/15360288.2010.526689","article-title":"Gout: Nonsteroidal anti-inflammatory drugs and colchicine to prevent painful flares during early urate-lowering therapy","volume":"24","author":"Kuritzky","year":"2010","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.010_bib45","first-page":"147","article-title":"Rhabdomyolysis induced by co-administration of fluvastatin and colchicine","volume":"74","author":"Sarullo","year":"2010","journal-title":"Monaldi Arch Chest Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.03.010_bib46","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/RHU.0b013e318156d977","article-title":"Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine","volume":"13","author":"Justiniano","year":"2007","journal-title":"J Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.03.010_bib47","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00002826-200209000-00008","article-title":"Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin","volume":"25","author":"Hsu","year":"2002","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.010_bib48","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3810\/pgm.2011.05.2284","article-title":"Managing your patient with gout: A review of treatment options","volume":"123","author":"Doghramji","year":"2011","journal-title":"Postgrad Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.010_bib49","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3109\/15360288.2010.526174","article-title":"Nonsteroidal anti-inflammatory drugs and colchicine to prevent gout flare during early urate-lowering therapy: Perspectives on alternative therapies and costs","volume":"24","author":"Peterson","year":"2010","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.03.010_bib50","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2174\/1568026054201640","article-title":"Global safety of coxibs and NSAIDs","volume":"5","author":"Pham","year":"2005","journal-title":"Curr Top Med Chem"},{"issue":"8","key":"10.1016\/j.semarthrit.2012.03.010_bib51","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/art.23929","article-title":"Recommendations for use of selective and nonselective nonsteroidal anti-inflammatory drugs: An American College of Rheumatology white paper","volume":"59","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.03.010_bib52","doi-asserted-by":"crossref","first-page":"d3450","DOI":"10.1136\/bmj.d3450","article-title":"Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: Population based case-control study","volume":"343","author":"Schmidt","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2012.03.010_bib53","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: Network meta-analysis","volume":"342","author":"Trelle","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2012.03.010_bib54","series-title":"Indocin (indomethacin) capsules [prescribing information]","year":"2007"},{"key":"10.1016\/j.semarthrit.2012.03.010_bib55","series-title":"Naprosyn (naproxen) tablets [prescribing information]","year":"2008"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.010_bib56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00002512-200724010-00002","article-title":"Management of gout in older adults: Barriers to optimal control","volume":"24","author":"Hoskison","year":"2007","journal-title":"Drugs Aging"},{"issue":"Suppl 5","key":"10.1016\/j.semarthrit.2012.03.010_bib57","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.3949\/ccjm.75.Suppl_5.S13","article-title":"The role of hyperuricemia and gout in kidney and cardiovascular disease","volume":"75","author":"Edwards","year":"2008","journal-title":"Cleve Clin J Med"},{"issue":"10","key":"10.1016\/j.semarthrit.2012.03.010_bib58","first-page":"1487","article-title":"Drug dosing adjustments in patients with chronic kidney disease","volume":"75","author":"Munar","year":"2007","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.semarthrit.2012.03.010_bib59","article-title":"Rilonacept (IL-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: Results of a phase 2 clinical trial","author":"Schumacher","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2012.03.010_bib60","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","article-title":"Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: Results of a double-blind, randomised study","volume":"70","author":"Schlesinger","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.010_bib61","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1 inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2012.03.010_bib62","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","article-title":"The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study","volume":"68","author":"Terkeltaub","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2012.03.010_bib63","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.03.010_bib64","first-page":"209","article-title":"Treatment of inflammasome-related disorders","author":"Lachmann","year":"2011"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.010_bib65","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/art.20102","article-title":"Quality of care indicators for gout management","volume":"50","author":"Mikuls","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.010_bib66","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/ar2738","article-title":"Gout","volume":"11","author":"Terkeltaub","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.semarthrit.2012.03.010_bib67","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/ard.2008.092619","article-title":"Opportunities for improving medication use and monitoring in gout","volume":"68","author":"Singh","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2012.03.010_bib68","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3899\/jrheum.081296","article-title":"Impact of a rheumatology consultation service on the diagnostic accuracy and management of gout in hospitalized patients","volume":"36","author":"Barber","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.03.010_bib69","series-title":"Uloric","year":"2011"},{"key":"10.1016\/j.semarthrit.2012.03.010_bib70","series-title":"Krystexxa","year":"2010"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017212000844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017212000844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:55:17Z","timestamp":1758732917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017212000844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0049017212000844"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2012.03.010","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Chronic Gouty Arthritis: It Is Not Just About Urate-Lowering Therapy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2012.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}